Articles By Estel Grace Masangkay

  1. J&J Buys Alios BioPharma, Acquires Antiviral Therapies 10/2/2014

    Johnson & Johnson and its company Janssen announced the acquisition of privately held clinical stage Alios BioPharma for an estimated $1.75 billion.

  2. FDA Awards $19M To 15 Orphan Drug Projects 10/2/2014

    The U.S. Food and Drug Administration (FDA) has given over $19 million in grants to encourage the development of drugs, biologics, and medical devices that address rare diseases. At least a quarter of the funds were allocated towards supporting projects that target pediatrics.

  3. Puma Biotech Posts Positive Phase 2 Data For NSCLC Drug 10/1/2014

    Development stage biopharmaceutical firm Puma Biotechnology reported positive early results from its Phase 2 trial investigating PB272 (neratinib) for the treatment of patients with HER2-mutated non-small cell lung cancer (NSCLC).

  4. Pfizer And Kyowa Hakko Kirin To Combine Immuno-Oncology Drugs 10/1/2014

    Pfizer announced that it has entered an agreement with Kyowa Hakko Kirin to explore the potential of the immuno-oncology combination of Kyowa’s mogamulizumab and Pfizer’s antibody PF-05082566 in patients with solid tumors.

  5. Rare Antibodies May Be Key To Future HIV Vaccine 9/30/2014

    A team of researchers from The Scripps Research Institute (TSRI) reported their findings about a single family of antibodies that could adapt to fight the elusive HIV virus and its different strains. Their discovery may one day provide the key to designing an effective HIV vaccine in the future.

  6. MIT Team Hacks Anthrax To Deliver Cancer Drugs 9/29/2014

    A team of chemists from the Massachusetts Institute of Technology (MIT) reported that they have turned to bacillus anthracis bacteria, the culprit behind anthrax infection, in order to deliver cancer drugs more effectively.

  7. FDA Grants Orphan Status To MabVax's Neuroblastoma Vaccine 9/29/2014

    Clinical stage oncology drug development firm MabVax Therapeutics announced that it has received the coveted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its vaccine targeting childhood cancer neuroblastoma.

  8. NIH Funds Phase 2 Of 'Tissue Chip For Drug Screening' Program 9/26/2014

    The National Institutes of Health (NIH) announced that it will award funds to support the next phase of the Tissue Chip for Drug Screening program, which will attempt to a build a human-like system to test drugs’ safety and efficacy.

  9. Genzyme Links With Universities In Gene Therapy Research 9/25/2014

    Sanofi company Genzyme announced that it has signed a research partnership with the University of Pennsylvania and the University of Florida for the development of a gene therapy that addresses the rare genetic disease Leber congenital amaurosis type 1 (LCA-1).

  10. Merck KGaA To Acquire Sigma-Aldrich For $17B 9/24/2014

    Germany-based Merck KGaA announced that it will acquire St. Louis-based chemical firm Sigma-Aldrich to strengthen its laboratory supplies business.